TdR诱导肝癌细胞株HepG2细胞周期同步化的效果  

To Investigate Cell Circle Phase of Synchronous Hepatocellular Carcinoma Cell of Line HepG2 Induced TdR

作　　者：白瑞霞[1] 王文礼[1] 李丽梅[1] 

机构地区：[1]内蒙古医学院生物化学与分子生物学教研室,呼和浩特010059

出　　处：《科学技术与工程》2008年第1期164-165,169,共3页Science Technology and Engineering

基　　金：内蒙古医学院重大科研项目(ny2004-zd-002)资助

摘　　要：取对数生长期的HepG2细胞,加入含TdR的培养基28h后,收集细胞,用PBS洗2次,加完全培养基,分别于12h和24h收集各组细胞。用流式细胞术分析细胞周期各时相细胞百分数。探讨TdR(胸腺嘧啶核苷)诱导人肝癌细胞株HepG2同步化后的细胞周期时相的变化。结果是TdR能较好地使肝癌细胞株HepG2同步化于G1期和G2期。TdR诱导细胞后,分别于12中h获得(63.62±2.82)%的G2/M期同步化细胞,24h后获得(75.24±0.17)%的G1期同步化细胞。HepG2 cells at logarithmic growth phase were choosen, culture media containing of TdR was added. After 28 hours plating , HepG2 cells were collected and washed twice with phosphate-buffered saline （PBS）. After PBS washed, 5 mL complete medium was added to each culture bottles. Cells of each group were collected after 12 hours and 24 hours respectively. Percentages of cells in each cell cycle phase were assayed by flow cytometry （FCM）. To investigate cell circle phase of synchronous human hepatocellular carcinoma cell of line HepG2 in- duced thymidine （TdR）, it is resulted that TdR can synchronized hepatocellular carcinoma cell of line HepG2 at G1 phase and G2 phase very well . FCM showed that after beeing induced by TdR, （ 63.62 ± 2.82 ） % and （75.24 ±0.17）% synchronous cancer cells in G1 phase and G2/M phase are achieved respectively.

关 键 词：肝癌 细胞周期同步化 流式细胞术 

分 类 号：R348.2[医药卫生—基础医学]